Skip to content
10-Q

Quarterly Report

AARDVARK THERAPEUTICS, INC. AARD

0001193125-26-210675

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 21.82M sh
Shares Diluted Q1 2026 · Mar 31, 2026 21.82M sh
Shares Diluted Q1 2026 · Mar 31, 2025 13.19M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$18.87M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$11.39M
Short Term Investments Q1 2026 · Mar 31, 2026 $28.76M
Short Term Investments Q1 2026 · Dec 31, 2025 $62.98M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $62.44M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $47.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 $86.99M
Stockholders Equity Q1 2026 · Dec 31, 2025 $106.63M
Stockholders Equity Q1 2026 · Mar 31, 2025 $150.69M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$54.64M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.6M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.55M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.6M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.55M
Current Assets Q1 2026 · Mar 31, 2026 $93.58M
Current Assets Q1 2026 · Dec 31, 2025 $111.89M
Total Assets Q1 2026 · Mar 31, 2026 $98.59M
Total Assets Q1 2026 · Dec 31, 2025 $117.18M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.99
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.71
Eps Basic Q1 2026 · Mar 31, 2026 −$0.99
Eps Basic Q1 2026 · Mar 31, 2025 −$0.71
Sga Expense Q1 2026 · Mar 31, 2026 $5.9M
Sga Expense Q1 2026 · Mar 31, 2025 $2.72M
Rd Expense Q1 2026 · Mar 31, 2026 $16.57M
Rd Expense Q1 2026 · Mar 31, 2025 $7.76M
Net Income Q1 2026 · Mar 31, 2026 −$21.59M
Net Income Q1 2026 · Mar 31, 2025 −$9.31M
Operating Income Q1 2026 · Mar 31, 2026 −$22.46M
Operating Income Q1 2026 · Mar 31, 2025 −$10.47M
Revenue Q1 2026 · Mar 31, 2026 $0